Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.
Quek L., Ferguson P., Metzner M., Ahmed I., Kennedy A., Garnett C., Jeffries S., Walter C., Piechocki K., Timbs A., Danby R., Raghavan M., Peniket A., Griffiths M., Bacon A., Ward J., Wheatley K., Vyas P., Craddock C.
Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post-allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients. An increased risk of relapse was observed in patients with mutations inWT1(P= .018),DNMT3A(P= .045),FLT3 ITD(P= .071), andTP53(P= .06), whereas mutations inIDH1were associated with a reduced risk of disease relapse (P= .018). In 29 patients, we additionally compared mutational profiles in bone marrow at diagnosis and relapse to study changes in clonal structure at relapse. In 13/29 patients, mutational profiles altered at relapse. In 9 patients, mutations present at relapse were not detected at diagnosis. In 15 patients, additional available pre-allo-SCT samples demonstrated that mutations identified posttransplant but not at diagnosis were detectable immediately prior to transplant in 2 of 15 patients. Taken together, these observations, if confirmed in larger studies, have the potential to inform the design of novel strategies to reduce posttransplant relapse highlighting the potential importance of post-allo-SCT interventions with a broad antitumor specificity in contrast to targeted therapies based on mutational profile at diagnosis.